Rockefeller Capital Management
RARE icon

Rockefeller Capital Management’s Ultragenyx Pharmaceutical RARE Stock Holding History

Rockefeller Capital Management’s Portfolio RARE Stock Details RARE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$61.6K Sell
1,845
-8,261
-82% -$205K ﹤0.01% 3252
2026
Q1 		$212K Buy
10,106
+2,390
+31% +$53.8K ﹤0.01% 2461
2025
Q4 		$177K Buy
7,716
+6,632
+612% +$218K ﹤0.01% 2434
2025
Q3 		$32.6K Buy
+1,084
New +$32.5K ﹤0.01% 3118
2023
Q2 		– Sell
-6,247
Closed -$249K – 1983
2023
Q1 		$249K Sell
6,247
-1,949
-24% -$83.6K ﹤0.01% 1693
2022
Q4 		$379K Buy
8,196
+1,360
+20% +$53.5K ﹤0.01% 1380
2022
Q3 		$282K Buy
6,836
+3,364
+97% +$173K ﹤0.01% 1496
2022
Q2 		$206K Buy
3,472
+58
+2% +$3.57K ﹤0.01% 1627
2022
Q1 		$247K Sell
3,414
-68
-2% -$4.73K ﹤0.01% 1604
2021
Q4 		$292K Buy
3,482
+1,965
+130% +$160K ﹤0.01% 1513
2021
Q3 		$136K Sell
1,517
-54
-3% -$4.88K ﹤0.01% 1734
2021
Q2 		$149K Buy
1,571
+58
+4% +$6.04K ﹤0.01% 1638
2021
Q1 		$172K Sell
1,513
-2,541
-63% -$346K ﹤0.01% 1377
2020
Q4 		$560K Buy
4,054
+1,885
+87% +$224K ﹤0.01% 875
2020
Q3 		$177K Buy
2,169
+55
+3% +$4.56K ﹤0.01% 1076
2020
Q2 		$165K Hold
2,114
– – ﹤0.01% 1010
2020
Q1 		$94K Sell
2,114
-463
-18% -$24K ﹤0.01% 1031
2019
Q4 		$110K Sell
2,577
-160
-6% -$6.6K ﹤0.01% 938
2019
Q3 		$117K Sell
2,737
-66
-2% -$3.58K ﹤0.01% 750
2019
Q2 		$178K Buy
2,803
+562
+25% +$35.8K ﹤0.01% 594
2019
Q1 		$156K Buy
2,241
+125
+6% +$7.14K ﹤0.01% 656
2018
Q4 		$92K Hold
2,116
– – ﹤0.01% 466
2018
Q3 		$162K Hold
2,116
– – ﹤0.01% 366
2018
Q2 		$163K Hold
2,116
– – ﹤0.01% 344
2018
Q1 		$108K Buy
+2,116
New +$107K ﹤0.01% 367

Other funds holding RARE

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $26.9B AUM 34.44% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $27.8B AUM 46.46% 1-Year Est. Return
FCM
Frontier Capital Management Boston, Massachusetts $10.7B AUM 67.78% 1-Year Est. Return

Rockefeller Capital Management's RARE Position: Q2 2026 in Review

Rockefeller Capital Management reduced its Ultragenyx Pharmaceutical (RARE) stake by 82% in Q2 2026, selling an estimated $205K and leaving 1,845 shares worth $61.6K. The position accounts for ﹤0.01% of the portfolio, ranked #3252.

Rockefeller Capital Management first reported a position in RARE in Q1 2018 and has held it in 25 quarters since. The position peaked at $560K in Q4 2020. 311 funds tracked by Wall St. Rank hold RARE as of Q2 2026.

  • Rockefeller Capital Management held 1,845 shares of Ultragenyx Pharmaceutical worth $61.6K as of Q2 2026.
  • Rockefeller Capital Management sold 8,261 Ultragenyx Pharmaceutical shares in Q2 2026, an estimated $205K.
  • Ultragenyx Pharmaceutical made up ﹤0.01% of Rockefeller Capital Management's portfolio in Q2 2026, its #3252 holding.
  • Rockefeller Capital Management first reported a position in Ultragenyx Pharmaceutical in Q1 2018 and has held it in 25 quarters since.
  • Rockefeller Capital Management's Ultragenyx Pharmaceutical position peaked at $560K in Q4 2020.
  • 311 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q2 2026.

Based on Rockefeller Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.